Michael Gelband’s Elevation Oncology ELEV Stock Holding History

Michael Gelband’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-597,017	Closed	-$219K	–	1665
2025 Q2	$219K	Buy	+597,017	New	+$199K	﹤0.01%	1300
2023 Q4	–	Sell	-999,546	Closed	-$662K	–	1614
2023 Q3	$662K	Sell	999,546 -499,773	-33%	-$505K	0.01%	1135
2023 Q2	$2.28M	Buy	+1,499,319	New	+$3.95M	0.02%	758

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Michael Gelband's ELEV Position: Q3 2025 in Review

Michael Gelband sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 597,017 shares — an estimated $219K sold.

Michael Gelband first reported a position in ELEV in Q2 2023 and held it in 3 quarters. The position peaked at $2.28M in Q2 2023. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Michael Gelband reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Michael Gelband sold 597,017 Elevation Oncology shares in Q3 2025, an estimated $219K.
Michael Gelband first reported a position in Elevation Oncology in Q2 2023 and held it in 3 quarters.
Michael Gelband's Elevation Oncology position peaked at $2.28M in Q2 2023.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.